Answer
Brodalumab, a human IgG2 monoclonal antibody, is expected to be degraded into small peptides and amino acids through catabolic pathways similar to those for endogenous IgG.
Sources for this answer
- Kyntheum 210 mg Solution for InjectionLeo Laboratories Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 7Document updated
Sources checked